Hongjie Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hongjie Xu has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Di Wu
Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China
3 shared publications- Dajiang Qin
Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
2 shared publications Jiali Lin
Bioland Laboratory, Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, China
2 shared publicationsQing Chen
Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China
2 shared publicationsRencun Liu
Shandong Province Key Laboratory of Detection Technology for Tumour Makers, School of Chemistry and Chemical Engineering, Linyi University, Linyi, China
2 shared publicationsRui Huang
The Fifth Clinical College, Guangzhou Medical University, Guangzhou, China
2 shared publications
Latest Publications
- Open Access
- 20 November 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (11)
Advances in Pathophysiology and Therapeutic Strategies for Atrophic Acne Scars
Background: Atrophic acne scars are a common and refractory dermatological complication that seriously affects patients' physical appearance and quality of life. Aims: This review aims to summarize the latest progress in the pathological mechanism and clinical treatment of atrophic acne scars, discuss the advantages and limitations of various therapies, and propose future research directions. Methods: A narrative review of the literature was conducted using PubMed, focusing on current evidence regarding the pathogenesis and management of atrophic acne scars. Results: The pathogenesis involves persistent inflammation, abnormal dermal collagen remodeling, stem cell dysfunction, and genetic and epigenetic regulation, forming a complex regulatory network. Multiple therapeutic options are available, including laser therapy, microneedling, radiofrequency, surgical techniques, filler injection, chemical peeling, and emerging biological therapies such as stem cells and extracellular vesicles. EV therapy represents a promising emerging regenerative approach, although supporting evidence remains preliminary, and larger controlled studies are required before routine clinical implementation. Conclusions: Multi‐omics, personalized precision treatment, and combined regimens represent promising future directions. This review may inform clinical practice and research on atrophic acne scars.
- 20 November 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (11)
Open AccessAdvances in Pathophysiology and Therapeutic Strategies for Atrophic Acne Scars
Background: Atrophic acne scars are a common and refractory dermatological complication that seriously affects patients' physical appearance and quality of life. Aims: This review aims to summarize the latest progress in the pathological mechanism and clinical treatment of atrophic acne scars, discuss the advantages and limitations of various therapies, and propose future research directions. Methods: A narrative review of the literature was conducted using PubMed, focusing on current evidence regarding the pathogenesis and management of atrophic acne scars. Results: The pathogenesis involves persistent inflammation, abnormal dermal collagen remodeling, stem cell dysfunction, and genetic and epigenetic regulation, forming a complex regulatory network. Multiple therapeutic options are available, including laser therapy, microneedling, radiofrequency, surgical techniques, filler injection, chemical peeling, and emerging biological therapies such as stem cells and extracellular vesicles. EV therapy represents a promising emerging regenerative approach, although supporting evidence remains preliminary, and larger controlled studies are required before routine clinical implementation. Conclusions: Multi‐omics, personalized precision treatment, and combined regimens represent promising future directions. This review may inform clinical practice and research on atrophic acne scars.
- Open Access
- 26 September 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Stem Cells
- Vol. 17 (9)
Human umbilical cord mesenchymal stromal cell-derived extracellular vesicles alleviate radiation induced pulmonary fibrosis
Pulmonary fibrosis, a chronic, fatal lung disease affecting millions worldwide, urgently needs more effective treatments. This article comments on the study by Wang et al , which proposed that human umbilical cord mesenchymal stromal cell-derived exosomes alleviate rats radiation induced pulmonary fibrosis. The study demonstrated that these exosomes suppressed inflammation, extracellular matrix deposition, and epithelial-mesenchymal transition by inhibition of AKT signaling in radiation-exposed alveolar epithelial cells. Despite these observations, aspects of the study merit further discussion. Most importantly, further confirmation is needed to prove that the therapeutic effect is exerted through the AKT signaling pathway. Moreover, the definitions of both mesenchymal stem cell and exosomes require further refinement, more rigorous terms should be mesenchymal stromal cell and extracellular vesicles. It seems apparent that this therapy will develop into one of great clinical value.
- 26 September 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Stem Cells
- Vol. 17 (9)
Open AccessHuman umbilical cord mesenchymal stromal cell-derived extracellular vesicles alleviate radiation induced pulmonary fibrosis
Pulmonary fibrosis, a chronic, fatal lung disease affecting millions worldwide, urgently needs more effective treatments. This article comments on the study by Wang et al , which proposed that human umbilical cord mesenchymal stromal cell-derived exosomes alleviate rats radiation induced pulmonary fibrosis. The study demonstrated that these exosomes suppressed inflammation, extracellular matrix deposition, and epithelial-mesenchymal transition by inhibition of AKT signaling in radiation-exposed alveolar epithelial cells. Despite these observations, aspects of the study merit further discussion. Most importantly, further confirmation is needed to prove that the therapeutic effect is exerted through the AKT signaling pathway. Moreover, the definitions of both mesenchymal stem cell and exosomes require further refinement, more rigorous terms should be mesenchymal stromal cell and extracellular vesicles. It seems apparent that this therapy will develop into one of great clinical value.
- Open Access
- 5 March 2025
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 16 (1) , 1-22
Preclinical study of engineering MSCs promoting diabetic wound healing and other inflammatory diseases through M2 polarization
Background: Diabetic foot ulcer (DFU) represents a common and severe complication of diabetes mellitus. Effective and safe treatments need to be developed. Mesenchymal stem cells (MSCs) have demonstrated crucial roles in tissue regeneration, wound repair and inflammation regulation. However, the function is limited. The safety and efficacy of gene-modified MSCs is unknown. Therefore, this study aimed to investigate whether genetically modified MSCs with highly efficient expression of anti-inflammatory factors promote diabetic wound repair by regulating macrophage phenotype transition. This may provide a new approach to treating diabetic wound healing. Methods: In this study, human umbilical cord-derived MSCs (hUMSCs) were genetically modified using recombinant lentiviral vectors to simultaneously overexpress three anti-inflammatory factors, interleukin (IL)-4, IL-10, IL-13 (MSCs-3IL). Cell counting kit-8, flow cytometry and differentiation assay were used to detect the criteria of MSCs. Overexpression efficiency was evaluated using flow cytometry, quantitative real-time PCR, Western blot, enzyme-linked immunosorbent assay, and cell scratch assay. We also assessed MSCs-3IL’s ability to modulate Raw264.7 macrophage phenotype using flow cytometry and quantitative real-time PCR. In addition, we evaluated diabetic wound healing through healing rate calculation, HE staining, Masson staining, and immunohistochemical analysis of PCNA, F4/80, CD31, CD86, CD206, IL-4, IL-10 and IL-13. In addition, we evaluated the safety of the MSCs-3IL cells and the effect of the cells on several other models of inflammation. Results: MSCs-3IL efficiently expressed high levels of IL-4 and IL-10 (mRNA transcription increased by 15,000-fold and 800,000-fold, protein secretion 400 and 200 ng/mL), and IL-13 (mRNA transcription increased by 950,000-fold, protein secretion 6 ng/mL). MSCs-3IL effectively induced phenotypic polarization of pro-inflammatory M1-like macrophages (M1) towards anti-inflammatory M2-like macrophages (M2). The enhancement of function does not change the cell phenotype. The dynamic distribution in vivo was normal and no karyotype variation and tumor risk was observed. In a mouse diabetic wound model, MSCs-3IL promoted diabetic wound healing with a wound closure rate exceeding 96% after 14 days of cell treatment. The healing process was aided by altering macrophage phenotype (reduced CD86 and increased CD206 expression) and accelerating re-epithelialization. Conclusions: In summary, our study demonstrates that genetically modified hUMSCs effectively overexpressed three key anti-inflammatory factors (IL-4, IL-10, IL-13). MSCs-3IL-based therapy enhances diabetic wound healing with high efficiency and safety. This suggests that genetically modified hUMSCs could be used as a novel therapeutic approach for DFU repair.
- 5 March 2025
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 16 (1) , 1-22
Open AccessPreclinical study of engineering MSCs promoting diabetic wound healing and other inflammatory diseases through M2 polarization
Background: Diabetic foot ulcer (DFU) represents a common and severe complication of diabetes mellitus. Effective and safe treatments need to be developed. Mesenchymal stem cells (MSCs) have demonstrated crucial roles in tissue regeneration, wound repair and inflammation regulation. However, the function is limited. The safety and efficacy of gene-modified MSCs is unknown. Therefore, this study aimed to investigate whether genetically modified MSCs with highly efficient expression of anti-inflammatory factors promote diabetic wound repair by regulating macrophage phenotype transition. This may provide a new approach to treating diabetic wound healing. Methods: In this study, human umbilical cord-derived MSCs (hUMSCs) were genetically modified using recombinant lentiviral vectors to simultaneously overexpress three anti-inflammatory factors, interleukin (IL)-4, IL-10, IL-13 (MSCs-3IL). Cell counting kit-8, flow cytometry and differentiation assay were used to detect the criteria of MSCs. Overexpression efficiency was evaluated using flow cytometry, quantitative real-time PCR, Western blot, enzyme-linked immunosorbent assay, and cell scratch assay. We also assessed MSCs-3IL’s ability to modulate Raw264.7 macrophage phenotype using flow cytometry and quantitative real-time PCR. In addition, we evaluated diabetic wound healing through healing rate calculation, HE staining, Masson staining, and immunohistochemical analysis of PCNA, F4/80, CD31, CD86, CD206, IL-4, IL-10 and IL-13. In addition, we evaluated the safety of the MSCs-3IL cells and the effect of the cells on several other models of inflammation. Results: MSCs-3IL efficiently expressed high levels of IL-4 and IL-10 (mRNA transcription increased by 15,000-fold and 800,000-fold, protein secretion 400 and 200 ng/mL), and IL-13 (mRNA transcription increased by 950,000-fold, protein secretion 6 ng/mL). MSCs-3IL effectively induced phenotypic polarization of pro-inflammatory M1-like macrophages (M1) towards anti-inflammatory M2-like macrophages (M2). The enhancement of function does not change the cell phenotype. The dynamic distribution in vivo was normal and no karyotype variation and tumor risk was observed. In a mouse diabetic wound model, MSCs-3IL promoted diabetic wound healing with a wound closure rate exceeding 96% after 14 days of cell treatment. The healing process was aided by altering macrophage phenotype (reduced CD86 and increased CD206 expression) and accelerating re-epithelialization. Conclusions: In summary, our study demonstrates that genetically modified hUMSCs effectively overexpressed three key anti-inflammatory factors (IL-4, IL-10, IL-13). MSCs-3IL-based therapy enhances diabetic wound healing with high efficiency and safety. This suggests that genetically modified hUMSCs could be used as a novel therapeutic approach for DFU repair.
- Open Access
- 18 November 2024
- Published by Springer Nature in Research Square
Preclinical study of engineering MSCs promoting diabetic wound healing and other inflammatory diseases through M2 polarization
Background Diabetic foot ulcer (DFU) represents a common and severe complication of diabetes mellitus. Effective and safe treatments need to be developed. Mesenchymal stem cells (MSCs) have demonstrated crucial roles in tissue regeneration, wound repair and inflammation regulation. However, the function is limited. The safety and efficacy of gene-modified MSCs is unknown. Therefore, this study aimed to investigate whether genetically modified MSCs with highly efficient expression of anti-inflammatory factors promote diabetic wound repair by regulating macrophage phenotype transition. This may provide a new approach to treating diabetic wound healing. Methods In this study, human umbilical cord-derived MSCs (hUMSCs) were genetically modified using recombinant lentiviral vectors to simultaneously overexpress three anti-inflammatory factors, interleukin 4, interleukin 10, interleukin 13 (MSCs-3IL). Cell counting kit-8, flow cytometry and differentiation assay were used to detect the criteria of MSCs. Overexpression efficiency was evaluated using flow cytometry, quantitative real-time PCR, Western blot, enzyme-linked immunosorbent assay, and cell scratch assay. We also assessed MSCs-3IL's ability to modulate Raw264.7 macrophage phenotype using flow cytometry and quantitative real-time PCR. In addition, we evaluated diabetic wound healing through healing rate calculation, HE staining, Masson staining, and immunohistochemical analysis of PCNA, F4/80, CD31, CD86, CD206, IL-4, IL-10 and IL-13. In addition, we evaluated the safety of the MSCs-3IL cells and the effect of the cells on several other models of inflammation. Results MSCs-3IL efficiently expressed high levels of IL-4 and IL-10 (mRNA transcription increased by 15,000-fold and 800,000-fold, protein secretion 400 and 200 ng/mL), and IL-13 (mRNA transcription increased by 950,000-fold, protein secretion 6 ng/mL). MSCs-3IL effectively induced phenotypic polarization of pro-inflammatory M1-like macrophages (M1) towards anti-inflammatory M2-like macrophages (M2). The enhancement of function does not change the cell phenotype. The dynamic distribution in vivo was normal and no karyotype variation and tumor risk was observed. In a mouse diabetic wound model, MSCs-3IL promoted diabetic wound healing with a wound closure rate exceeding 96% after 14 days of cell treatment. The healing process was aided by altering macrophage phenotype (reduced CD86 and increased CD206 expression) and accelerating re-epithelialization. Conclusions In summary, our study demonstrates that genetically modified hUMSCs effectively overexpressed three key anti-inflammatory factors (IL-4, IL-10, IL-13). MSCs-3IL-based therapy enhances diabetic wound healing with high efficiency and safety. This suggests that genetically modified hUMSCs could be used as a novel therapeutic approach for DFU repair.
- 18 November 2024
- Published by Springer Nature in Research Square
Open AccessPreclinical study of engineering MSCs promoting diabetic wound healing and other inflammatory diseases through M2 polarization
Background Diabetic foot ulcer (DFU) represents a common and severe complication of diabetes mellitus. Effective and safe treatments need to be developed. Mesenchymal stem cells (MSCs) have demonstrated crucial roles in tissue regeneration, wound repair and inflammation regulation. However, the function is limited. The safety and efficacy of gene-modified MSCs is unknown. Therefore, this study aimed to investigate whether genetically modified MSCs with highly efficient expression of anti-inflammatory factors promote diabetic wound repair by regulating macrophage phenotype transition. This may provide a new approach to treating diabetic wound healing. Methods In this study, human umbilical cord-derived MSCs (hUMSCs) were genetically modified using recombinant lentiviral vectors to simultaneously overexpress three anti-inflammatory factors, interleukin 4, interleukin 10, interleukin 13 (MSCs-3IL). Cell counting kit-8, flow cytometry and differentiation assay were used to detect the criteria of MSCs. Overexpression efficiency was evaluated using flow cytometry, quantitative real-time PCR, Western blot, enzyme-linked immunosorbent assay, and cell scratch assay. We also assessed MSCs-3IL's ability to modulate Raw264.7 macrophage phenotype using flow cytometry and quantitative real-time PCR. In addition, we evaluated diabetic wound healing through healing rate calculation, HE staining, Masson staining, and immunohistochemical analysis of PCNA, F4/80, CD31, CD86, CD206, IL-4, IL-10 and IL-13. In addition, we evaluated the safety of the MSCs-3IL cells and the effect of the cells on several other models of inflammation. Results MSCs-3IL efficiently expressed high levels of IL-4 and IL-10 (mRNA transcription increased by 15,000-fold and 800,000-fold, protein secretion 400 and 200 ng/mL), and IL-13 (mRNA transcription increased by 950,000-fold, protein secretion 6 ng/mL). MSCs-3IL effectively induced phenotypic polarization of pro-inflammatory M1-like macrophages (M1) towards anti-inflammatory M2-like macrophages (M2). The enhancement of function does not change the cell phenotype. The dynamic distribution in vivo was normal and no karyotype variation and tumor risk was observed. In a mouse diabetic wound model, MSCs-3IL promoted diabetic wound healing with a wound closure rate exceeding 96% after 14 days of cell treatment. The healing process was aided by altering macrophage phenotype (reduced CD86 and increased CD206 expression) and accelerating re-epithelialization. Conclusions In summary, our study demonstrates that genetically modified hUMSCs effectively overexpressed three key anti-inflammatory factors (IL-4, IL-10, IL-13). MSCs-3IL-based therapy enhances diabetic wound healing with high efficiency and safety. This suggests that genetically modified hUMSCs could be used as a novel therapeutic approach for DFU repair.
- Open Access
- 18 July 2022
- Published by Springer Nature in Journal of Materials Science: Materials in Medicine
- Vol. 33 (8) , 1-14
A hybrid hydrogel encapsulating human umbilical cord mesenchymal stem cells enhances diabetic wound healing
Background: Diabetic wound is a severe complication of diabetes. Stem cell is considered as a promising therapy for diabetic skin wounds. Hydrogel can supply niche for cells adhesion and survival to improve the efficacy of stem cell therapy, but the development of hydrogel with suitable properties remains a great challenge. Thus, our study was conducted to combine an optimized hydrogel with stem cell to improve complex diabetic wound treatment.Methods: This study constructed a hydrogel with low toxicity and adjustable mechanical properties from gelatin methacrylate (GelMA) and chitosan-catechol (Chi-C), and encapsulated human umbilical cord-mesenchymal stem cells (hUMSCs) to repair full-thickness diabetic wound.Results: We explored the relationship between mechanical stiffness and cell proliferation and differentiation potency, and found 10% GelMA hydrogel with an optimal stiffness improved hUMSCs adhesion, proliferation, and differentiation potency maintenance in vitro. Assistant with optimized hydrogel encapsulating hUMSCs, diabetic wound healing process was greatly accelerated, including accelerated wound closure, inhibited secretion of inflammatory factors TNF-α and IL-1β, promoted vascular regeneration and collagen deposition after treatment of hUMSCs.Conclusions: The optimized hydrogel encapsulating hUMSCs improved diabetic wound healing, and has a broad implication for the treatment of diabetic complication.
- 18 July 2022
- Published by Springer Nature in Journal of Materials Science: Materials in Medicine
- Vol. 33 (8) , 1-14
Open AccessA hybrid hydrogel encapsulating human umbilical cord mesenchymal stem cells enhances diabetic wound healing
Background: Diabetic wound is a severe complication of diabetes. Stem cell is considered as a promising therapy for diabetic skin wounds. Hydrogel can supply niche for cells adhesion and survival to improve the efficacy of stem cell therapy, but the development of hydrogel with suitable properties remains a great challenge. Thus, our study was conducted to combine an optimized hydrogel with stem cell to improve complex diabetic wound treatment.Methods: This study constructed a hydrogel with low toxicity and adjustable mechanical properties from gelatin methacrylate (GelMA) and chitosan-catechol (Chi-C), and encapsulated human umbilical cord-mesenchymal stem cells (hUMSCs) to repair full-thickness diabetic wound.Results: We explored the relationship between mechanical stiffness and cell proliferation and differentiation potency, and found 10% GelMA hydrogel with an optimal stiffness improved hUMSCs adhesion, proliferation, and differentiation potency maintenance in vitro. Assistant with optimized hydrogel encapsulating hUMSCs, diabetic wound healing process was greatly accelerated, including accelerated wound closure, inhibited secretion of inflammatory factors TNF-α and IL-1β, promoted vascular regeneration and collagen deposition after treatment of hUMSCs.Conclusions: The optimized hydrogel encapsulating hUMSCs improved diabetic wound healing, and has a broad implication for the treatment of diabetic complication.
- 20 October 2012
- Published by China Science Publishing & Media Ltd. in Journal of Inorganic Materials
- Vol. 27 (10) , 1047-1052
Fatigue Life Investigation of PZT Ceramics by MSP Method
The cycle fatigue of PZT ceramic under different stress was investigated by modified small punch (MSP) tests. The research results show that residual strength and piezoelectric constant decrease with increasing cycle stress, which is attributed to crack propagation during cyclic stress process. The value of fatigue crack propagation (n) is calculated to be 395 according to the relationship between maximum stress and fatigue life. The fatigue life under series cycle maximum stress can be induce by fatigue crack propagation. Below the maximum strength of 79.1 MPa, the PZT ceramics can be used over 5 years
- 20 October 2012
- Published by China Science Publishing & Media Ltd. in Journal of Inorganic Materials
- Vol. 27 (10) , 1047-1052
Fatigue Life Investigation of PZT Ceramics by MSP Method
The cycle fatigue of PZT ceramic under different stress was investigated by modified small punch (MSP) tests. The research results show that residual strength and piezoelectric constant decrease with increasing cycle stress, which is attributed to crack propagation during cyclic stress process. The value of fatigue crack propagation (n) is calculated to be 395 according to the relationship between maximum stress and fatigue life. The fatigue life under series cycle maximum stress can be induce by fatigue crack propagation. Below the maximum strength of 79.1 MPa, the PZT ceramics can be used over 5 years